Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

The Next Big Canadian Cannabis IPO

Sep 29, 2016 • 10:07 AM EDT
Investing_money (1).jpg
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Although the legal cannabis industry is in the first inning of what will prove to be a multi-decade growth cycle investors must conduct ample due diligence before investing.

From the United Kingdom to Canada, the legal cannabis industry has made significant strides over the last year, a trend that we expect to not only continue but to accelerate as new markets open and existing ones develop.

Capital Markets Become More Receptive to Cannabis

Capital markets have become more receptive to cannabis businesses over the last year and this is especially true for licensed medical cannabis producers in Canada.

The Canadian cannabis industry saw a major boost after Justin Trudeau and the Liberal Party won the Canadian general election as they have announced the intention to make cannabis legalization a priority.

The stocks levered to this growth have seen their respective share price move significantly higher over the year and even though we see further upside from current levels, investors should wait for a pullback in the sector or for a new opportunity.

An Undervalued New Opportunity

Capital markets have become more receptive to cannabis businesses over the last year. In October, Emblem Health Corp, a licensed medical cannabis producer in Canada will have its initial public offering on the TSX venture exchange.

Emblem is comprised of three distinct divisions which can create value for each other as well as improve the value proposition of the entire company.

Although the company’s strategy across its three verticals of cannabis production, patient education and pharmaceutical production, will take time to execute in full, benefits will quickly materialize as the industry continues to move forward.

A Ground Floor Opportunity

Emblem is led by its founders and a management team with a proven track record of success prior to having started the company. Since its inception, management has been able to execute on its plan and put the company in a position attractive to capital markets.

The Emblem team has built and managed multi-billion dollar companies. The company’s management, its founders, advisors, and employees have invested $6 million into the company.

John Stewart is the president of Emblem Pharmaceuticals, which is focused on developing new dosage forms of cannabinoid medication and revolutionizing how patients consume cannabis. Prior to joining Emblem, Stewart was the president and CEO of Purdue Pharma Canada and Purdue Pharma U.S., one of the largest privately held pharmaceutical companies in the world. Stewart was responsible for the launch of 11 new products, including OxyContin.

A Massive Growth Opportunity

Since it just recently received its sales license from Health Canada, we expect to see Emblem show consistent growth and improving fundamentals on a year-over-year basis for the foreseeable future.

Emblem’s pre-IPO valuation is below $25 million and this is attractive as it is significantly lower than other licensed medical cannabis producers in Canada. Although Emblem has a long road ahead, we expect to see the company grow quickly due to its customer friendly infrastructure, premium product, and its focus on education.

By early 2017, we expect to see the market catch on with Emblem’s potential. This has created an attractive investment opportunity for investors who are looking for an undervalued investment opportunity in the legal cannabis industry.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.